Loading
AMO959 is a small-molecule inhibitor from Novartis Pharmaceuticals, in registered phase 2 trials for prostate cancer.
AMO959 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Novartis Pharmaceuticals, in prostate cancer. Described in the registry record as a by1298 by101298 dna damage response inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
Described in the registry record as a by1298 by101298 dna damage response inhibitor; the trial entries below carry the sponsor's wording.
1.AMO959 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"AMO959" OR ABSTRACT:"AMO959" OR TITLE:"BY1298" OR ABSTRACT:"BY1298" OR TITLE:"BY101298" OR ABSTRACT:"BY101298") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AMO959, not a curated reading list.
Shares Advanced Accelerator Applications (Novartis), Novartis, Prostate cancer and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Prostate cancer and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis and the tag pipeline.
Shares Novartis and the tags pipeline, registry-only.
Shares Novartis and the tags pipeline, registry-only.
Shares Novartis and the tags pipeline, registry-only.
Shares Advanced Accelerator Applications (Novartis), Prostate cancer and the tag pipeline.